5TZL

Structure of transthyretin in complex with the kinetic stabilizer 201


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.40 Å
  • R-Value Free: 0.167 
  • R-Value Work: 0.133 
  • R-Value Observed: 0.134 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.

Connelly, S.Mortenson, D.E.Choi, S.Wilson, I.A.Powers, E.T.Kelly, J.W.Johnson, S.M.

(2017) Bioorg Med Chem Lett 27: 3441-3449

  • DOI: 10.1016/j.bmcl.2017.05.080
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by monomer misfolding and misassembly, appears to cause degenerative diseases in humans known as the transthyretin amyloidoses, based on human genetic, biochemical and ...

    Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by monomer misfolding and misassembly, appears to cause degenerative diseases in humans known as the transthyretin amyloidoses, based on human genetic, biochemical and pharmacologic evidence. Small molecules that bind to the generally unoccupied thyroxine binding pockets in the native TTR tetramer kinetically stabilize the tetramer, slowing subunit dissociation proportional to the extent that the molecules stabilize the native state over the dissociative transition state-thereby inhibiting amyloidogenesis. Herein, we use previously reported structure-activity relationship data to develop two semi-quantitative algorithms for identifying the structures of potent and selective transthyretin kinetic stabilizers/amyloidogenesis inhibitors. The viability of these prediction algorithms, in particular the more robust in silico docking model, is perhaps best validated by the clinical success of tafamidis, the first-in-class drug approved in Europe, Japan, South America, and elsewhere for treating transthyretin aggregation-associated familial amyloid polyneuropathy. Tafamidis is also being evaluated in a fully-enrolled placebo-controlled clinical trial for its efficacy against TTR cardiomyopathy. These prediction algorithms will be useful for identifying second generation TTR kinetic stabilizers, should these be needed to ameliorate the central nervous system or ophthalmologic pathology caused by TTR aggregation in organs not accessed by oral tafamidis administration.


    Organizational Affiliation

    Department of Biochemistry & Molecular Biology, Indiana University, School of Medicine, Van Nuys Medical Sciences Building, MS 0013D, 635 Barnhill Dr, Indianapolis, IN 46202, United States. Electronic address: johnstm@iu.edu.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Transthyretin
A, B
127Homo sapiensMutation(s): 0 
Gene Names: TTRPALB
Find proteins for P02766 (Homo sapiens)
Go to UniProtKB:  P02766
NIH Common Fund Data Resources
PHAROS  P02766
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
IIH
Query on IIH

Download CCD File 
A, B
4-(7-chloro-1,3-benzoxazol-2-yl)-2,6-diiodophenol
C13 H6 Cl I2 N O2
VVINERCPKRFEOL-UHFFFAOYSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
OCS
Query on OCS
A,BL-PEPTIDE LINKINGC3 H7 N O5 SCYS
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.40 Å
  • R-Value Free: 0.167 
  • R-Value Work: 0.133 
  • R-Value Observed: 0.134 
  • Space Group: P 21 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 43.265α = 90
b = 85.467β = 90
c = 64.285γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
HKL-2000data scaling
PHASERphasing
DENZOdata reduction

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Disease (NIH/NIDDK)United StatesDK 46335
The Skaggs Institute of Chemical BiologyUnited States--
Lita Annenberg Hazen FoundationUnited States--
Indiana University School of Medicine, Department of Biochemistry and Molecular BiologyUnited States--
The George E. Hewitt Foundation for Medical ResearchUnited States--

Revision History 

  • Version 1.0: 2017-06-28
    Type: Initial release
  • Version 1.1: 2017-07-19
    Changes: Database references
  • Version 1.2: 2017-09-20
    Changes: Author supporting evidence
  • Version 1.3: 2019-12-25
    Changes: Author supporting evidence, Derived calculations